A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Clinical trial NCT05537740 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05537740
- Sponsor
- Bayer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-11
- Primary completion
- 2027-04-30
- Enrollment
- 129
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.